Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2008, for Innovative Acquisitions Corp. (not Puma Biotechnology, Inc., as indicated in the metadata). The company is a Delaware corporation classified as a "shell company" and a "blank check" company. It was incorporated on April 27, 2007, and is currently in the development stage with no active operations other than seeking a business combination through acquisition or merger.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2008 | Cumulative from Inception (Apr 27, 2007) to Mar 31, 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,491) | $(19,584) |
| Cash and Cash Equivalents | $2,166 | $2,166 |
| Total Assets | $2,166 | $2,166 |
| Total Liabilities | $0 | $0 |
| Stockholders' Equity | $2,166 | $2,166 |
| Common Shares Outstanding | 3,000,000 | 3,000,000 |
Profitability & Margins: The company has generated no revenue and has no profit margins. All expenses are general and administrative costs related to organizational efforts and regulatory filings.
Liquidity & Debt: The company has no debt. Liquidity is minimal, with cash balances of $2,166 as of March 31, 2008.
Material Changes vs. Prior Period
- Cash Position: Cash increased by $759 during the quarter, rising from $1,407 at December 31, 2007, to $2,166 at March 31, 2008.
- Capital Contributions: The increase in cash was driven by $5,250 in capital contributions from directors during the quarter, partially offset by operating losses of $4,491.
- Accumulated Deficit: The accumulated deficit grew from $(15,093) to $(19,584) due to the current quarter's net loss.
Outlook, Risks, and Management Commentary
Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. The company has not generated revenue and is unlikely to do so in the immediate future without a business combination.
Business Plan: The primary objective for the next 12 months is to identify and acquire a target company. The company does not restrict its search to any specific industry or geography.
Risks:
- Financing Dependency: Operations depend entirely on financial support from shareholders and the ability to obtain equity financing.
- Target Risk: Potential targets may be financially unstable, early-stage, or in high-risk industries.
- Blank Check Status: As a shell company with no specific business plan, the company is subject to regulations limiting the sale of its securities in many jurisdictions.
Unusual Items: There are no off-balance sheet arrangements. The net loss consists entirely of legal, accounting, and audit fees required for SEC reporting.
Investor Verification Checklist
- Company Identity: Verify that the filing is for Innovative Acquisitions Corp., not Puma Biotechnology, Inc.
- Cash Runway: Confirm if the $2,166 cash balance is sufficient to cover filing fees and search costs for the next 12 months without additional capital.
- Capital Contributions: Verify the source and terms of the $5,250 capital contribution from directors.
- Going Concern Status: Assess the likelihood of the company securing a business combination before cash is depleted.
- Share Count: Confirm the 3,000,000 shares outstanding and the par value of $0.0001 per share.